Table 2 Subsequent treatment and response of 102 included patients
Treatment response | No of patients (%) |
|---|---|
Treatment post PARPi | |
Platinum-based chemotherapy | 52 (51.0) |
Non-platinum chemotherapy | 22 (21.6) |
PARPi + antiangiogenic agent | 18 (17.6) |
Clinical trial | 2 (2.0) |
Surgery | 6 (5.9) |
Radiotherapy | 2 (2.0) |
Response to subsequent treatment of PARPi maintenance therapy | |
Complete response | 6 (5.9) |
Partial response | 36 (35.3) |
Stable disease | 25 (24.5) |
Progressive disease | 35 (34.3) |